Lixisenatide dosing & administration
Short-acting prandial GLP-1 receptor agonist for postprandial glucose control
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Dosing
How much Lixisenatide do I take?
Subcutaneous: A small injection into the fatty layer just under the skin — the same way insulin is given.
Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.
Titration schedule
10 mcg
Frequency
Once daily
Duration
Days 1-14
FDA-label (Adlyxin) starting dose given once daily for 14 days using the green starter pen; injected in abdomen, thigh, or upper arm within one hour before the first meal of the day [6].
20 mcg
Frequency
Once daily
Duration
From day 15 onward
FDA-label maintenance dose, started on day 15 using the burgundy pen for ongoing type 2 diabetes glycemic control [6].
Timing
Best time to take
Inject once daily within one hour before the first meal of the day, preferably before the same meal each day. [6] If a dose is missed, inject it within one hour before the next meal. [6]
With food?
Timing to a meal matters: lixisenatide's glucose-lowering effect is strongest on the meal after the injection and weaker at later meals. [6] Take time-sensitive oral medications (antibiotics, acetaminophen) at least 1 hour before the injection. [6]
If stacking
Lixisenatide should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting your dose
Increase if
- You've tolerated the current dose for the recommended period without significant side effects
- Therapeutic goals haven't been met at the current dose level
- Your healthcare provider recommends dose escalation based on your response
- Lab work or clinical assessments support a higher dose
Decrease if
- Side effects are bothersome or impacting daily life despite management strategies
- You experience any signs of an adverse reaction
- Lab results indicate the need for dose reduction
- Your healthcare provider recommends a lower dose based on your response
Signs of right dose
- Therapeutic goals being met with minimal side effects
- Stable and consistent response to treatment
- Lab values or clinical markers trending in the right direction
- Good tolerance with manageable or absent side effects
Administration
How do I use Lixisenatide?
Reconstitution
What you need
Injection
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
Storage
Before reconstitution
Before first use, store ADLYXIN pens in the refrigerator at 36–46°F (2–8°C). [6] Do not freeze. [6] Keep the pen in its original package to protect it from light. [6] Check the expiration date before use.
After reconstitution
Not applicable — ADLYXIN is a ready-to-use prefilled pen; nothing is mixed. After first use, store it at up to 86°F (30°C) and replace the cap after each use to protect it from light. [6] Discard the pen 14 days after first use. [6] Do not use the solution if it is not clear and colorless or contains particles. [6]
Signs of degradation — discard the vial
Sample daily schedule
As prescribed (once daily)
As prescribed by your healthcare provider injection
Site: subcutaneous injection—rotate sites if applicable
Maintain a consistent schedule for optimal results with Lixisenatide. Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.
Safety
Is Lixisenatide safe?
Side effects
Commonly reported: Nausea, Vomiting, Diarrhea, Headache
Less common: Injection Site Reactions
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Lixisenatide
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Lixisenatide should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Flagged pairings
- Other GLP-1 Receptor Agonists — Redundant mechanism of action with increased gastrointestinal side effects and no additional benefit
- DPP-4 Inhibitors — Overlapping incretin pathway stimulation provides minimal additional glucose-lowering effect
- Time-sensitive oral medications — Lixisenatide delays gastric emptying. Take antibiotics and acetaminophen at least 1 hour before the injection, and oral contraceptives at least 1 hour before or 11 hours after it [6]
Published research
What the studies show
Trujillo JM, Goldman J · 2017
Systematic review of the GetGoal programme: lixisenatide 20 µg once daily lowered HbA1c by 0.46–0.99% and 2-hour postprandial glucose by 55.86–143.43 mg/dL, with weight change of −2.96 to +0.3 kg. Severe hypoglycaemia was very rare (under 1.5%) and there was no increased risk of cardiovascular events; the most common adverse events were transient, mild-to-moderate nausea and vomiting.
Meier JJ, Menge BA, Schenker N, et al. · 2020
In 28 metformin-treated adults with type 2 diabetes, lixisenatide mainly lowered postprandial glucose and insulin glargine mainly fasting glucose. After breakfast, lixisenatide slowed gastric emptying and reduced insulin secretion and glucagon; combining it with glargine enhanced glucose lowering through complementary mechanisms.
Meier JJ, Rosenstock J, Hincelin-Méry A, et al. · 2015
142 insulin glargine-treated adults were randomised to lixisenatide 20 µg or liraglutide 1.2 or 1.8 mg for 8 weeks. Lixisenatide lowered post-breakfast glucose more and delayed gastric emptying more than either liraglutide dose; liraglutide raised 24-hour heart rate by 9 bpm against 3 bpm with lixisenatide. Symptomatic hypoglycaemia was more frequent with lixisenatide, gastrointestinal adverse events with liraglutide.
Yabe D, Iizuka K, Baxter M, et al. · 2021
Post-hoc analysis of LixiLan JP-L in Japanese adults uncontrolled on basal insulin: with iGlarLixi (insulin glargine plus lixisenatide, 1 unit:1 µg) the share with residual hyperglycaemia fell from 32.5% to 15.7% at 26 weeks, while it rose to 36.9% on glargine alone, and HbA1c fell 0.72 percentage points more with iGlarLixi.
Gerstein HC, Hess S, Claggett B, et al. · 2022
Research (2022) demonstrates lixisenatide's efficacy in clinical treatment and therapeutic applications.
Sanofi-Aventis · 2023
FDA label: 10 mcg SC once daily for 14 days, then 20 mcg once-daily maintenance for type 2 diabetes; injected within one hour before the first meal.
Head to head
Lixisenatide compared
Studied for
Conditions Lixisenatide has been researched in
Want the full picture?
The complete Lixisenatide research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.